Controlled-Release Oxaliplatin Nanocarrier
Official patent title
Chitosan-hybridized zinc phosphate/hydroxyapatite nanostructure-based drug delivery system
Arabic title: نظام لتوصيل الدواء قائم على بنية نانوية من فوسفات الزنك/هيدروكسي أباتيت مهجّنة بالكيتوسان
Invention
Invention
Problem
Oxaliplatin is used in cancer treatment but has poor solubility and can cause substantial adverse effects. Existing carrier materials still leave a need for a porous delivery structure that can load and release the drug under defined conditions.
Why it matters
A characterized carrier could support research into controlled oxaliplatin delivery and formulation. The disclosed loading and release behavior is preclinical and does not demonstrate improved outcomes or safety in patients.
Approach
The system uses a porous zinc phosphate core enclosed by a hydroxyapatite nanorod shell and wrapped with chitosan through hydrogen bonding. Oxaliplatin is loaded into pores and onto the shell and polymer through noncovalent interactions to form a controlled-release nanocomposite.
Who may benefit
Potential beneficiaries include drug-delivery and biomaterials researchers, oncology formulation teams, nanocomposite manufacturers, and pharmaceutical organizations evaluating oxaliplatin carriers.
Potential value
The architecture combines a porous inorganic core, a hydroxyapatite nanorod shell, and a chitosan outer layer, with specified surface area, pore size, drug-loading conditions, and extended-release measurements in one carrier design.
Background
Background
Oxaliplatin can inhibit cancer-cell proliferation through platinum–DNA interactions, but its limited solubility and adverse effects motivate research into alternative delivery systems. Hydroxyapatite offers chemical stability, surface area, and ion-exchange capacity, although its hydrophilic nature can limit drug-carrier performance. Chitosan contributes adsorption capacity and a functional polymer coating. The patent combines these materials with a porous zinc phosphate core to create a multilayer carrier intended to load oxaliplatin through hydrogen bonding, electrostatic interactions, ion exchange, and pore entrapment.
Technology overview
Technology overview
The nanocomposite has a zinc phosphate core, a hydroxyapatite nanorod shell, and a chitosan wrapping. Claimed embodiments specify 120–140 m²/g BET surface area, 25–35 nm average pore diameter, and loading of 300–350 mg oxaliplatin per gram of composite at pH 6–8 and 20–30 °C. The disclosure reports at least 50% release after 22 hours and complete release after 140 hours at pH 7.4, alongside XRD, FT-IR, SEM, and HRTEM characterization.
Potential applications
Potential applications
- Preclinical controlled-delivery research for oxaliplatin.
- Nanocarrier formulation studies for colorectal-cancer research.
- Evaluation of porous core–shell biomaterials for drug loading.
- Extended-release studies using noncovalent drug–carrier interactions.
Evidence-supported advantages
Evidence-supported advantages
- Combines zinc phosphate, hydroxyapatite nanorods, and chitosan in a layered carrier.
- Provides a high-surface-area porous structure with defined pore dimensions.
- Reports oxaliplatin loading of 300–350 mg per gram under specified conditions.
- Documents extended release from 22 to 140 hours at pH 7.4.
- Uses multiple noncovalent loading mechanisms rather than covalent drug attachment.
Development stage
Development stage
Nanocomposite synthesis, structural characterization, drug loading, and release experiments are described; clinical performance and commercialization were not established.
Commercial opportunity
Commercial opportunity
The carrier may support research licensing or co-development with nanomedicine and oncology-formulation groups. Progress toward a product would require reproducible scale-up, sterility and stability work, comparative release studies, biodistribution, toxicity, in-vivo efficacy, and regulatory development. Comparison with free oxaliplatin would be essential.
Patent classifications
Patent classifications
WIPO IPC
- A61K9/20Preparations for medical, dental or toiletry purposes
- A61K31/555Preparations for medical, dental or toiletry purposes
- B82Y5/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures
CPC
- A61K9/2072Preparations for medical, dental or toiletry purposes
- A61K9/0092Preparations for medical, dental or toiletry purposes
- A61K9/5161Preparations for medical, dental or toiletry purposes
- A61K9/2009Preparations for medical, dental or toiletry purposes
- A61K31/555Preparations for medical, dental or toiletry purposes
- A61K9/205Preparations for medical, dental or toiletry purposes
- A61K9/5115Preparations for medical, dental or toiletry purposes
- A61K9/5036Preparations for medical, dental or toiletry purposes
- B82Y5/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures
Inventors
Inventors
- First inventorAhmed A Allam
- InventorHassan A. Rudayni
- InventorMostafa R. Abukhadra
- InventorIslam R. Sayed
Keywords
Keywords
- oxaliplatin
- chitosan
- zinc phosphate
- hydroxyapatite
- core-shell nanocomposite
- controlled release
- drug delivery
- porous carrier
Patent document and drawings
Patent document and drawings
The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.